Symbols / KLTO $0.52 +0.81%
KLTO Chart
About
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 56.66M |
| Enterprise Value | 26.60M | Income | -11.29M | Sales | — |
| Book/sh | 0.14 | Cash/sh | 0.10 | Dividend Yield | — |
| Payout | 0.00% | Employees | 3 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | 3.72 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 82.76 |
| Current Ratio | 83.69 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.30 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -71.63% |
| ROE | -198.28% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 108.09M |
| Shs Float | 65.83M | Short Float | 3.27% | Short Ratio | 0.65 |
| Short Interest | — | 52W High | 3.91 | 52W Low | 0.11 |
| Beta | 2.23 | Avg Volume | 3.29M | Volume | 2.18M |
| Target Price | — | Recom | None | Prev Close | $0.52 |
| Price | $0.52 | Change | 0.81% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.52
Latest analyst target
3. DCF / Fair value
$-0.98
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.52
Low
—
High
—
Mean
—
- Klotho Neurosciences pivots to Greenland minerals with new name - Stock Titan Mon, 09 Mar 2026 12
- Klotho Neurosciences Completes Greenland Mines Acquisition Merger - The Globe and Mail hu, 12 Mar 2026 02
- Klotho Neurosciences: What’s Behind The Nine-Fold Rise In KLTO Stock? - Forbes ue, 10 Jun 2025 07
- Klotho Neurosciences Shareholders Approve Reverse Stock Split - TipRanks ue, 17 Feb 2026 08
- KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS - PR Newswire Wed, 18 Jun 2025 07
- Biotech Klotho pivots to $68B Greenland metals trove for the West - Stock Titan Wed, 04 Mar 2026 08
- Klotho Neurosciences Stock Skyrockets On Anti-Aging Gene Therapy Breakthrough: Retail Traders Over The Moon - MSN Sat, 29 Nov 2025 06
- Why Klotho Surged 50% Overnight? - StocksToTrade hu, 10 Jul 2025 07
- Klotho Neurosciences (KLTO) sets 34.6M-share stock and warrant sale - Stock Titan Mon, 23 Feb 2026 08
- Why Is KLTO Stock Down? Hidden Dangers Every Investor Must Know Today - vocal.media Wed, 30 Jul 2025 11
- Klotho Neurosciences faces Nasdaq delisting risk - Investing.com Mon, 21 Apr 2025 07
- Director El-Dada Riad Hussein granted 350,000 KLTO shares at $0.00 - Stock Titan Fri, 06 Mar 2026 08
- 3 Penny Stocks to Watch Now, 5/15/25 - TipRanks hu, 15 May 2025 07
- Klotho Neurosciences enters agreement to sell Series C preferred stock to Sigma9 Capital - Investing.com Mon, 08 Dec 2025 08
- Klotho Neurosciences (NASDAQ: KLTO) registers 75.1M shares; 34.6M private placement - Stock Titan ue, 24 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 350000 | — | — | Stock Award(Grant) at price 0.00 per share. | EL-DADA RIAD HUSSEIN | Director | — | 2026-03-04 00:00:00 | D |
| 1 | 350000 | — | — | Stock Award(Grant) at price 0.00 per share. | MCGARITY JON W | Director | — | 2026-03-04 00:00:00 | D |
| 2 | 350000 | — | — | Stock Award(Grant) at price 0.00 per share. | ZENTMAN SAMUEL M | Director | — | 2026-03-04 00:00:00 | D |
| 3 | 350000 | — | — | Stock Award(Grant) at price 0.00 per share. | HIRSCHMAN SHALOM Z | Director | — | 2026-03-04 00:00:00 | D |
| 4 | 2500000 | — | — | Stock Award(Grant) at price 0.00 per share. | SINKULE JOSEPH | Chief Executive Officer | — | 2026-03-04 00:00:00 | D |
| 5 | 2500000 | — | — | Stock Award(Grant) at price 0.00 per share. | LEBLANC JEFF | Chief Financial Officer | — | 2026-03-04 00:00:00 | D |
| 6 | 200000 | — | — | Stock Award(Grant) at price 0.00 per share. | LEBLANC JEFF | Chief Financial Officer | — | 2025-08-25 00:00:00 | D |
| 7 | 14641 | — | — | Stock Award(Grant) at price 0.00 per share. | MCGARITY JON W | Director | — | 2025-08-05 00:00:00 | D |
| 8 | 153494 | — | — | Stock Award(Grant) at price 0.00 per share. | ZENTMAN SAMUEL M | Director | — | 2025-08-05 00:00:00 | D |
| 9 | 70149 | — | — | Stock Award(Grant) at price 0.00 per share. | HIRSCHMAN SHALOM Z | Director | — | 2025-08-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -5.79M | -631.24K | -574.23K | -1.11M |
| TotalUnusualItems | -1.96K | |||
| TotalUnusualItemsExcludingGoodwill | -1.96K | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -6.15M | -707.46K | -598.59K | -1.11M |
| EBITDA | -5.79M | -631.24K | -574.23K | -1.11M |
| EBIT | -5.79M | -631.24K | -574.23K | -1.11M |
| NetInterestIncome | -356.60K | -76.21K | -24.37K | 0.00 |
| InterestExpense | 356.60K | 76.21K | 24.37K | 0.00 |
| NormalizedIncome | -6.15M | -707.46K | -598.59K | -1.11M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -6.15M | -707.46K | -598.59K | -1.11M |
| TotalExpenses | 5.54M | 631.32K | 574.37K | 1.11M |
| TotalOperatingIncomeAsReported | -5.54M | -631.32K | -574.37K | -1.11M |
| DilutedAverageShares | 19.25M | 1.04B | 1.04B | 1.04B |
| BasicAverageShares | 19.25M | 1.04B | 1.04B | 1.04B |
| DilutedEPS | -0.32 | -0.00 | -0.00 | -0.00 |
| BasicEPS | -0.32 | -0.00 | -0.00 | -0.00 |
| DilutedNIAvailtoComStockholders | -6.15M | -707.46K | -598.59K | -1.11M |
| NetIncomeCommonStockholders | -6.15M | -707.46K | -598.59K | -1.11M |
| NetIncome | -6.15M | -707.46K | -598.59K | -1.11M |
| NetIncomeIncludingNoncontrollingInterests | -6.15M | -707.46K | -598.59K | -1.11M |
| NetIncomeContinuousOperations | -6.15M | -707.46K | -598.59K | -1.11M |
| TaxProvision | 0.00 | 0.00 | ||
| PretaxIncome | -6.15M | -707.46K | -598.59K | -1.11M |
| OtherIncomeExpense | -253.53K | 78.00 | 147.00 | 44.00 |
| OtherNonOperatingIncomeExpenses | -251.57K | 78.00 | 147.00 | 44.00 |
| GainOnSaleOfSecurity | -1.96K | |||
| NetNonOperatingInterestIncomeExpense | -356.60K | -76.21K | -24.37K | 0.00 |
| InterestExpenseNonOperating | 356.60K | 76.21K | 24.37K | 0.00 |
| OperatingIncome | -5.54M | -631.32K | -574.37K | -1.11M |
| OperatingExpense | 5.54M | 631.32K | 574.37K | 1.11M |
| SellingGeneralAndAdministration | 5.54M | 631.32K | 574.37K | 1.11M |
| GeneralAndAdministrativeExpense | 5.54M | 631.32K | 574.37K | 1.11M |
| OtherGandA | 2.89M | 631.32K | 572.97K | 287.92K |
| SalariesAndWages | 2.65M | 0.00 | 1.40K | 821.15K |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 27.08M | 15.13M | 15.13M | 15.13M |
| ShareIssued | 27.08M | 15.13M | 15.13M | 15.13M |
| NetDebt | 208.01K | 1.46M | 1.27M | |
| TotalDebt | 271.75K | 1.47M | 1.35M | |
| TangibleBookValue | -1.11M | -1.61M | -1.03M | 288.88K |
| InvestedCapital | 1.46M | 2.04M | 2.53M | 1.03M |
| WorkingCapital | -1.09M | -1.61M | -1.03M | 289.38K |
| NetTangibleAssets | -1.11M | -1.61M | -1.03M | 289.38K |
| CommonStockEquity | 1.19M | 571.72K | 1.18M | 1.03M |
| PreferredStockEquity | 505.00 | 505.00 | ||
| TotalCapitalization | 1.19M | 571.72K | 1.18M | 1.03M |
| TotalEquityGrossMinorityInterest | 1.19M | 571.72K | 1.18M | 1.03M |
| StockholdersEquity | 1.19M | 571.72K | 1.18M | 1.03M |
| RetainedEarnings | -10.56M | -3.92M | -3.22M | -2.62M |
| AdditionalPaidInCapital | 11.75M | 4.49M | 3.54M | 3.54M |
| CapitalStock | 2.71K | 1.51K | 856.39K | 104.99K |
| CommonStock | 2.71K | 1.51K | 855.89K | 104.49K |
| PreferredStock | 0.00 | 0.00 | 505.00 | 505.00 |
| TotalLiabilitiesNetMinorityInterest | 1.27M | 1.62M | 1.36M | 15.13K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 24.49K | 0.00 | 0.00 | 0.00 |
| DerivativeProductLiabilities | 24.49K | 0.00 | ||
| CurrentLiabilities | 1.25M | 1.62M | 1.36M | 15.13K |
| CurrentDebtAndCapitalLeaseObligation | 271.75K | 1.47M | 1.35M | |
| CurrentDebt | 271.75K | 1.47M | 1.35M | |
| OtherCurrentBorrowings | 135.00K | |||
| CurrentNotesPayable | 271.75K | 1.33M | 1.35M | 0.00 |
| PayablesAndAccruedExpenses | 975.78K | 153.72K | 12.76K | 15.13K |
| CurrentAccruedExpenses | 912.10K | 2.46K | 4.74K | 0.00 |
| Payables | 63.69K | 151.26K | 8.01K | 15.13K |
| AccountsPayable | 63.69K | 151.26K | 8.01K | 15.13K |
| TotalAssets | 2.46M | 2.19M | 2.54M | 1.04M |
| TotalNonCurrentAssets | 2.30M | 2.19M | 2.21M | 736.98K |
| GoodwillAndOtherIntangibleAssets | 2.30M | 2.19M | 2.21M | 736.98K |
| OtherIntangibleAssets | 2.30M | 2.19M | 2.21M | 736.98K |
| CurrentAssets | 157.81K | 6.65K | 329.54K | 304.52K |
| PrepaidAssets | 94.07K | 3.84K | 3.67K | 3.67K |
| Receivables | 250.00K | 0.00 | ||
| DuefromRelatedPartiesCurrent | 250.00K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 63.74K | 2.81K | 75.87K | 300.85K |
| CashAndCashEquivalents | 63.74K | 2.81K | 75.87K | 300.85K |
| CashFinancial | 63.74K | 2.81K | 75.87K | 300.85K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -3.07M | -460.80K | -724.98K | -284.02K |
| RepurchaseOfCapitalStock | -120.00K | 0.00 | ||
| IssuanceOfDebt | 2.18M | 0.00 | ||
| IssuanceOfCapitalStock | 295.00K | 0.00 | 750.00K | 250.00K |
| CapitalExpenditure | -123.50K | -13.89K | -125.41K | |
| InterestPaidSupplementalData | 2.46K | 78.50K | 19.62K | 0.00 |
| IncomeTaxPaidSupplementalData | 551.59K | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 63.74K | 2.81K | 75.87K | 300.85K |
| BeginningCashPosition | 2.81K | 75.87K | 300.85K | 334.87K |
| ChangesInCash | 60.93K | -73.06K | -224.98K | -34.02K |
| FinancingCashFlow | 3.13M | 350.00K | 500.00K | 250.00K |
| CashFlowFromContinuingFinancingActivities | 3.13M | 350.00K | 500.00K | 250.00K |
| NetOtherFinancingCharges | 778.94K | 350.00K | 500.00K | 250.00K |
| NetCommonStockIssuance | 175.00K | 0.00 | 750.00K | 250.00K |
| CommonStockPayments | -120.00K | 0.00 | ||
| CommonStockIssuance | 295.00K | 0.00 | 750.00K | 250.00K |
| NetIssuancePaymentsOfDebt | 2.18M | 0.00 | ||
| NetShortTermDebtIssuance | 2.18M | 0.00 | ||
| ShortTermDebtIssuance | 2.18M | 0.00 | ||
| InvestingCashFlow | -123.50K | 23.85K | -125.41K | 0.00 |
| CashFlowFromContinuingInvestingActivities | -123.50K | 23.85K | -125.41K | 0.00 |
| NetIntangiblesPurchaseAndSale | -123.50K | 23.85K | -125.41K | 0.00 |
| SaleOfIntangibles | 0.00 | 37.74K | ||
| PurchaseOfIntangibles | -123.50K | -13.89K | -125.41K | 0.00 |
| OperatingCashFlow | -2.95M | -446.92K | -599.57K | -284.02K |
| CashFlowFromContinuingOperatingActivities | -2.95M | -446.92K | -599.57K | -284.02K |
| ChangeInWorkingCapital | 150.57K | 260.54K | -2.38K | 3.85K |
| ChangeInOtherCurrentLiabilities | 60.02K | 0.00 | ||
| ChangeInPayablesAndAccruedExpense | 180.78K | 260.71K | -2.38K | 2.24K |
| ChangeInAccruedExpense | 1.06M | -2.28K | 4.74K | 0.00 |
| ChangeInPayable | -883.68K | 263.00K | -7.12K | 2.24K |
| ChangeInAccountPayable | -187.57K | 104.00K | -7.12K | -12.90K |
| ChangeInTaxPayable | -568.11K | 0.00 | ||
| ChangeInIncomeTaxPayable | -568.11K | 0.00 | ||
| ChangeInPrepaidAssets | -90.23K | -173.00 | 0.00 | 1.61K |
| OtherNonCashItems | 391.75K | |||
| StockBasedCompensation | 2.65M | 0.00 | 1.40K | 821.15K |
| AssetImpairmentCharge | 10.00K | 0.00 | ||
| OperatingGainsLosses | 1.96K | |||
| GainLossOnInvestmentSecurities | 1.96K | |||
| NetIncomeFromContinuingOperations | -6.15M | -707.46K | -598.59K | -1.11M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for KLTO
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|